LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 112

Search options

  1. Article ; Online: The long and winding road to pathogen reduction of platelets, red blood cells and whole blood.

    Rebulla, Paolo

    British journal of haematology

    2019  Volume 186, Issue 5, Page(s) 655–667

    Abstract: Pathogen reduction technologies (PRTs) have been developed to further reduce the current very low risks of acquiring transfusion-transmitted infections and promptly respond to emerging infectious threats. An entire portfolio of PRTs suitable for all ... ...

    Abstract Pathogen reduction technologies (PRTs) have been developed to further reduce the current very low risks of acquiring transfusion-transmitted infections and promptly respond to emerging infectious threats. An entire portfolio of PRTs suitable for all blood components is not available, but the field is steadily progressing. While PRTs for plasma have been used for many years, PRTs for platelets, red blood cells (RBC) and whole blood (WB) were developed more slowly, due to difficulties in preserving cell functions during storage. Two commercial platelet PRTs use ultra violet (UV) A and UVB light in the presence of amotosalen or riboflavin to inactivate pathogens' nucleic acids, while a third experimental PRT uses UVC light only. Two PRTs for WB and RBC have been tested in experimental clinical trials with storage limited to 21 or 35 days, due to unacceptably high RBC storage lesion beyond these time limits. This review summarizes pre-clinical investigations and selected outcomes from clinical trials using the above PRTs. Further studies are warranted to decrease cell storage lesions after PRT treatment and to test PRTs in different medical and surgical conditions. Affordability remains a major administrative obstacle to PRT use, particularly so in geographical regions with higher risks of transfusion-transmissible infections.
    MeSH term(s) Blood Platelets/metabolism ; Blood Preservation/methods ; Erythrocytes/metabolism ; Humans
    Language English
    Publishing date 2019-07-14
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.16093
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Pathogen Reduction for Platelets-A Review of Recent Implementation Strategies.

    Rebulla, Paolo / Prati, Daniele

    Pathogens (Basel, Switzerland)

    2022  Volume 11, Issue 2

    Abstract: The development of pathogen reduction technologies (PRT) for labile blood components is a long-pursued goal in transfusion medicine. While PRT for red blood cells and whole blood are still in an early phase of development, different PRT platforms for ... ...

    Abstract The development of pathogen reduction technologies (PRT) for labile blood components is a long-pursued goal in transfusion medicine. While PRT for red blood cells and whole blood are still in an early phase of development, different PRT platforms for plasma and platelets are commercially available and routinely used in several countries. This review describes complementary strategies recommended by the US FDA to mitigate the risk of septic reactions in platelet recipients, including PRT and large-volume delayed sampling, and summarizes the main findings of recent reports discussing economical and organizational issues of platelet PRT implementation. Sophisticated mathematical analytical models are available to determine the impact of PRT on platelet costs, shortages and outdates in different settings. PRT implementation requires careful planning to ensure the availability of sufficient economical, technological and human resources. A phased approach was used in most PRT implementation programs, starting with adult and pediatric immunocompromised patients at higher risk of developing septic platelet transfusion reactions. Overall, the reviewed studies show that significant progress has been made in this area, although additional efforts will be necessary to reduce the storage lesion of PRT platelets and to expand the sustainable applicability of PRT to all labile blood components.
    Language English
    Publishing date 2022-01-24
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens11020142
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A pathogen reduction clinical trial in retrospect.

    Rebulla, Paolo

    Blood transfusion = Trasfusione del sangue

    2017  Volume 15, Issue 4, Page(s) 329–332

    MeSH term(s) Blood Component Transfusion/methods ; Blood Component Transfusion/standards ; Disinfection/methods ; Disinfection/standards ; Female ; Humans ; Italy ; Male ; Practice Guidelines as Topic
    Language English
    Publishing date 2017-04-10
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2135732-8
    ISSN 2385-2070 ; 0041-1787 ; 1723-2007
    ISSN (online) 2385-2070
    ISSN 0041-1787 ; 1723-2007
    DOI 10.2450/2017.0340-16
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Pathogen Reduction for Platelets—A Review of Recent Implementation Strategies

    Rebulla, Paolo / Prati, Daniele

    Pathogens. 2022 Jan. 24, v. 11, no. 2

    2022  

    Abstract: The development of pathogen reduction technologies (PRT) for labile blood components is a long-pursued goal in transfusion medicine. While PRT for red blood cells and whole blood are still in an early phase of development, different PRT platforms for ... ...

    Abstract The development of pathogen reduction technologies (PRT) for labile blood components is a long-pursued goal in transfusion medicine. While PRT for red blood cells and whole blood are still in an early phase of development, different PRT platforms for plasma and platelets are commercially available and routinely used in several countries. This review describes complementary strategies recommended by the US FDA to mitigate the risk of septic reactions in platelet recipients, including PRT and large-volume delayed sampling, and summarizes the main findings of recent reports discussing economical and organizational issues of platelet PRT implementation. Sophisticated mathematical analytical models are available to determine the impact of PRT on platelet costs, shortages and outdates in different settings. PRT implementation requires careful planning to ensure the availability of sufficient economical, technological and human resources. A phased approach was used in most PRT implementation programs, starting with adult and pediatric immunocompromised patients at higher risk of developing septic platelet transfusion reactions. Overall, the reviewed studies show that significant progress has been made in this area, although additional efforts will be necessary to reduce the storage lesion of PRT platelets and to expand the sustainable applicability of PRT to all labile blood components.
    Keywords Food and Drug Administration ; adults ; humans ; medicine ; pathogens ; risk
    Language English
    Dates of publication 2022-0124
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens11020142
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: Pathogen Reduction for Platelets—A Review of Recent Implementation Strategies

    Paolo Rebulla / Daniele Prati

    Pathogens, Vol 11, Iss 142, p

    2022  Volume 142

    Abstract: The development of pathogen reduction technologies (PRT) for labile blood components is a long-pursued goal in transfusion medicine. While PRT for red blood cells and whole blood are still in an early phase of development, different PRT platforms for ... ...

    Abstract The development of pathogen reduction technologies (PRT) for labile blood components is a long-pursued goal in transfusion medicine. While PRT for red blood cells and whole blood are still in an early phase of development, different PRT platforms for plasma and platelets are commercially available and routinely used in several countries. This review describes complementary strategies recommended by the US FDA to mitigate the risk of septic reactions in platelet recipients, including PRT and large-volume delayed sampling, and summarizes the main findings of recent reports discussing economical and organizational issues of platelet PRT implementation. Sophisticated mathematical analytical models are available to determine the impact of PRT on platelet costs, shortages and outdates in different settings. PRT implementation requires careful planning to ensure the availability of sufficient economical, technological and human resources. A phased approach was used in most PRT implementation programs, starting with adult and pediatric immunocompromised patients at higher risk of developing septic platelet transfusion reactions. Overall, the reviewed studies show that significant progress has been made in this area, although additional efforts will be necessary to reduce the storage lesion of PRT platelets and to expand the sustainable applicability of PRT to all labile blood components.
    Keywords platelets ; pathogen reduction ; platelet transfusion ; transmissible infections ; Medicine ; R
    Subject code 630
    Language English
    Publishing date 2022-01-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: From pH to MALDI-TOF: hundreds of spotted opportunities?

    Rebulla, Paolo

    Journal of proteomics

    2012  Volume 76 Spec No., Page(s) 270–274

    Abstract: Current protocols for quality assurance of platelet concentrates used in transfusion therapy include evaluation of platelet count and pH, in vitro measurements of platelet lysis, membrane activation and microparticle release and assays of platelet ... ...

    Abstract Current protocols for quality assurance of platelet concentrates used in transfusion therapy include evaluation of platelet count and pH, in vitro measurements of platelet lysis, membrane activation and microparticle release and assays of platelet ability to respond to aggregation stimuli and to hypotonic shock. Unfortunately, these assays show limited correlation to post-transfusion platelet survival and recovery in the recipient. This requires validation of platelet collection and storage systems with expensive and time consuming autologous transfusion studies in healthy volunteers with radiolabeled platelets. Furthermore, platelets from some donors show increased lesion during storage for reasons that are incompletely understood. This editorial discusses recent strides in proteomic technology which open interesting perspectives for improving current procedures for quality assurance of platelet concentrates and increasing the safety and effectiveness of platelet transfusion in medical and surgical conditions. This article is part of a Special Issue entitled: Integrated omics.
    MeSH term(s) Animals ; Blood Platelets/cytology ; Blood Platelets/metabolism ; Cell Membrane/metabolism ; Cell Survival ; Humans ; Hydrogen-Ion Concentration ; Platelet Activation ; Platelet Transfusion ; Proteomics/methods ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
    Language English
    Publishing date 2012-12-05
    Publishing country Netherlands
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2400835-7
    ISSN 1876-7737 ; 1874-3919
    ISSN (online) 1876-7737
    ISSN 1874-3919
    DOI 10.1016/j.jprot.2012.07.044
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain.

    Rebulla, Paolo / Querol, Sergio / Pupella, Simonetta / Prati, Daniele / Delgadillo, Joaquin / De Angelis, Vincenzo

    Frontiers in cell and developmental biology

    2022  Volume 9, Page(s) 812038

    Abstract: Most public cord blood banking programs are currently facing financial difficulties due to a progressive decline in the number of cord blood transplants performed worldwide and to a high discard rate of the donated units caused by progressively ... ...

    Abstract Most public cord blood banking programs are currently facing financial difficulties due to a progressive decline in the number of cord blood transplants performed worldwide and to a high discard rate of the donated units caused by progressively increasing thresholds of the stem cell dose required to perform safe and effective hemopoietic cord blood transplants. Recycling a proportion of unused cord blood units to prepare novel cord blood components obtained with minimal manipulation (platelets, plasma, red blood cells) and to develop more technologically complex products regulated in the US as Cellular and Gene Therapy Products and in Europe as Advanced Therapy Medicinal Products [e.g. virus-specific T cells (VST), natural killer (NK) cells, induced pluripotent stem cells (iPSCs) is a promising strategy to increase the therapeutic value and reduce the financial deficits of public cord blood banking. Based on encouraging preliminary evidences reported in the literature, additional laboratory studies, large multicenter clinical trials and international regulatory harmonization are necessary to achieve these important goals. This article describes organizational, methodological and regulatory advancements developed in Italy and Spain to promote the clinical use of cord blood platelets, plasma and red blood cells.
    Language English
    Publishing date 2022-01-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2737824-X
    ISSN 2296-634X
    ISSN 2296-634X
    DOI 10.3389/fcell.2021.812038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Platelet efficacy revisited?

    Rebulla, Paolo

    Transfusion

    2010  Volume 50, Issue 4, Page(s) 745–747

    MeSH term(s) Blood Platelets/cytology ; Blood Platelets/physiology ; Cell Separation/methods ; Humans ; Leukocytes/cytology ; Platelet Transfusion/adverse effects ; Platelet Transfusion/standards ; Research Design/standards
    Language English
    Publishing date 2010-04
    Publishing country United States
    Document type Editorial
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/j.1537-2995.2010.02619.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Cord blood banking and transplantation in 2010.

    Rebulla, Paolo

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

    2010  Volume 42, Issue 3, Page(s) 253–254

    MeSH term(s) Blood Banks/standards ; Blood Donors/psychology ; Cord Blood Stem Cell Transplantation/methods ; Cord Blood Stem Cell Transplantation/standards ; Donor Selection ; Hematopoietic Stem Cell Transplantation ; Humans ; Public Opinion ; Quality Control ; Specimen Handling/methods ; Specimen Handling/standards ; Blood Banking/methods
    Language English
    Publishing date 2010-03-30
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 2046795-3
    ISSN 1878-1683 ; 1473-0502
    ISSN (online) 1878-1683
    ISSN 1473-0502
    DOI 10.1016/j.transci.2010.03.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Response to "An unbalanced study that lacks power: a caution about IPTAS".

    Rebulla, Paolo / Milani, Silvano / Grazzini, Giuliano

    Transfusion

    2017  Volume 57, Issue 9, Page(s) 2285–2287

    Language English
    Publishing date 2017-09
    Publishing country United States
    Document type Letter
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.14210
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top